PMID- 26587691
OWN - NLM
STAT- MEDLINE
DCOM- 20160926
LR  - 20191210
IS  - 1744-7658 (Electronic)
IS  - 1354-3784 (Linking)
VI  - 25
IP  - 2
DP  - 2016
TI  - An overview of new GLP-1 receptor agonists for type 2 diabetes.
PG  - 145-58
LID - 10.1517/13543784.2016.1123249 [doi]
AB  - INTRODUCTION: The increasing prevalence of type 2 diabetes mellitus (T2DM) and 
      the eventual need for multiple medications in most patients stimulated the 
      development of new drug classes to reduce plasma glucose levels. The GLP-1 
      receptor agonists (GLP-1RAs) are established as an option for treatment of T2DM 
      after metformin. They are also effective in reducing body weight but current 
      GLP-1RAs have to be given by subcutaneous injection daily or once weekly. AREAS 
      COVERED: This review focuses on the new GLP-1RAs currently undergoing 
      development, some of which require less frequent subcutaneous administration and 
      others that are being developed in oral formulations that may favor patient 
      adherence. EXPERT OPINION: The new GLP-1RAs may have the benefit of requiring 
      less frequent subcutaneous dosing or being active by oral administration. 
      However, cardiovascular outcome trials have shown that DPP4 inhibitors are 
      neutral for cardiovascular events and the first cardiovascular outcome trial with 
      lixisenatide reported similar results, whereas the trial with the SGLT2 inhibitor 
      empagliflozin showed a reduction in cardiovascular events. These findings in 
      patients with high cardiovascular risk may favor the use of SGLT2 inhibitors as a 
      second line treatment after metformin but there should still be an important role 
      for novel GLP-1RAs, especially when weight reduction is required.
FAU - Tomlinson, Brian
AU  - Tomlinson B
AD  - a Research Center for Translational Medicine , Shanghai East Hospital Affiliated 
      to Tongji University School of Medicine , Shanghai , China.
AD  - b Department of Medicine & Therapeutics , Prince of Wales Hospital, The Chinese 
      University of Hong Kong , Shatin , Hong Kong.
FAU - Hu, Miao
AU  - Hu M
AD  - b Department of Medicine & Therapeutics , Prince of Wales Hospital, The Chinese 
      University of Hong Kong , Shatin , Hong Kong.
FAU - Zhang, Yuzhen
AU  - Zhang Y
AD  - a Research Center for Translational Medicine , Shanghai East Hospital Affiliated 
      to Tongji University School of Medicine , Shanghai , China.
FAU - Chan, Paul
AU  - Chan P
AD  - c Division of Cardiology, Department of Internal Medicine , Wan Fang Hospital, 
      Taipei Medical University , Taipei city , Taiwan.
FAU - Liu, Zhong-Min
AU  - Liu ZM
AD  - d Department of Cardiac Surgery , Shanghai East Hospital, Tongji University , 
      Shanghai , China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20151217
PL  - England
TA  - Expert Opin Investig Drugs
JT  - Expert opinion on investigational drugs
JID - 9434197
RN  - 0 (Glucagon-Like Peptide-1 Receptor)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (SLC5A2 protein, human)
RN  - 0 (Sodium-Glucose Transporter 2)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Body Weight/drug effects
MH  - Diabetes Mellitus, Type 2/*drug therapy/physiopathology
MH  - Drug Design
MH  - Glucagon-Like Peptide-1 Receptor/*agonists
MH  - Humans
MH  - Hypoglycemic Agents/administration & dosage/pharmacology/*therapeutic use
MH  - Injections, Subcutaneous
MH  - Medication Adherence
MH  - Sodium-Glucose Transporter 2
MH  - Sodium-Glucose Transporter 2 Inhibitors
OTO - NOTNLM
OT  - Efpeglenatide
OT  - GLP-1
OT  - GLP-1 receptor agonist
OT  - glymera
OT  - semaglutide
OT  - type 2 diabetes mellitus
EDAT- 2015/11/21 06:00
MHDA- 2016/09/27 06:00
CRDT- 2015/11/21 06:00
PHST- 2015/11/21 06:00 [entrez]
PHST- 2015/11/21 06:00 [pubmed]
PHST- 2016/09/27 06:00 [medline]
AID - 10.1517/13543784.2016.1123249 [doi]
PST - ppublish
SO  - Expert Opin Investig Drugs. 2016;25(2):145-58. doi: 
      10.1517/13543784.2016.1123249. Epub 2015 Dec 17.